Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks

被引：0

|

作者：

Forst, Thomas

Guthrie, Robert

Goldenberg, Ronald

Yee, Jacqueline

Vijapurkar, Ujjwala

Meininger, Gary

Stein, Peter

机构：

来源：

DIABETES | 2013年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1098-P

引用

收藏

页码：A284 / A284

页数：1

相关论文

共 50 条

[41] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
Kovacs, Christopher S.
Seshiah, Veeraswamy
Merker, Ludwig
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Stella, Peter
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2014, 63 : A273 - A273
[42] BUDGET IMPACT ANALYSIS OF UTILIZING CANAGLIFLOZIN (CANA) FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN AN UNITED STATES HEALTH PLAN
Vo, L.
Martin, S.
[J]. VALUE IN HEALTH, 2014, 17 (03) : A243 - A243
[43] Effect of Colesevelam HCl (COL) as an Add-On to Pioglitazone (PIO) on Lipid Particles in Type 2 Diabetes Mellitus (T2DM)
Jones, Michael R.
Ford, Daniel M.
Baz-Hecht, Merav
Tao, Ben
Truitt, Kenneth E.
Chou, Hubert S.
[J]. DIABETES, 2013, 62 : A302 - A302
[44] Canagliflozin (CANA) Improves Glycemic Control and Reduces Body Weight and Blood Pressure (BP) in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) With or Without Other Antihyperglycemic Agents (AHAs)
Hollander, Priscilla
Mathieu, Chantal
Tong, Cindy
Canovatchel, William
Meininger, Gary
[J]. DIABETES, 2015, 64 : A662 - A663
[45] Characteristics of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Therapy with Canagliflozin
Martin, Silas C.
Henk, Henry J.
Chow, Wing
[J]. DIABETES, 2014, 63 : A307 - A307
[46] Cost-Effectiveness Analysis of Canagliflozin (CANA) vs. Maximally Titrated Glimepiride (GLIM) as an Add-on to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States
Neslusan, Cheryl
Martin, Silas
Teschemaker, Anna
Vo, Lien
Johansen, Pierre
Willis, Michael
[J]. DIABETES, 2014, 63 : A309 - A310
[47] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Who Were, or Were Not, on Antihyperglycemic Agents (AHAs) at Screening
Gonzalez-Galvez, Guillermo
Kim, Kyoung-Ah
Jodar, Esteban
Alba, Maria
Tong, Cindy
Meininger, Gary
[J]. DIABETES, 2014, 63 : A280 - A280
[48] Addition of Alogliptin vs Uptitration of Pioglitazone Dose in Type 2 Diabetes Mellitus (T2DM) Patients on Metformin Plus Pioglitazone Therapy
Bosi, Emanuele
Ellis, Graham
Moneuse, Patrick
Wilson, Craig
Fleck, Penny
[J]. DIABETES, 2010, 59 : A148 - A148
[49] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Based on Age and Estimated Glomerular Filtration Rate (eGFR)
Gilbert, Richard E.
Weir, Matthew R.
Fioretto, Paola
Law, Gordon
Usiskin, Keith
Meininger, Gary
[J]. DIABETES, 2014, 63 : A267 - A267
[50] BAYESIAN NETWORK META-ANALYSIS (NMA) TO ASSESS THE RELATIVE EFFICACY OF CANAGLIFLOZIN MONOTHERAPY OVER 26 WEEKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Schroeder, M.
Taieb, V
Belhadi, D.
Seyla-Hammer, C.
Hemels, M.
Nielsen, A. T.
[J]. VALUE IN HEALTH, 2015, 18 (03) : A56 - A56

← 1 2 3 4 5 →